Refine
Year of publication
Document Type
- Preprint (259)
- Article (171)
- Doctoral Thesis (1)
Has Fulltext
- yes (431)
Is part of the Bibliography
- no (431)
Keywords
- LHC (8)
- Heavy Ion Experiments (6)
- ALICE experiment (4)
- Hadron-Hadron Scattering (3)
- Hadron-Hadron scattering (experiments) (3)
- Heavy Ions (3)
- Heavy-ion collision (3)
- pp collisions (3)
- ALICE (2)
- Beauty production (2)
- Charm physics (2)
- Pb–Pb collisions (2)
- Single electrons (2)
- ALICE detector (1)
- Anti-nuclei (1)
- Brain tumor (1)
- Centrality Class (1)
- Centrality Selection (1)
- Comparison with QCD (1)
- EWSR1 (1)
- Electron-pion identification (1)
- Elliptic flow (1)
- FDG-PET/CT (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- Gene fusion (1)
- HBT (1)
- HNSCC (1)
- Hadron production (1)
- Head neck cancer (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion collisions (1)
- ISR (1)
- Immunotherapy (1)
- Inclusive spectra (1)
- Induction therapy (1)
- Intensity interferometry (1)
- Invariant Mass Distribution (1)
- Ionisation energy loss (1)
- Jets (1)
- MN1 (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Monte Carlo (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Neural network (1)
- Neuroepithelial (1)
- Neurooncology (1)
- Nrf2 (1)
- Nuclear modification factor (1)
- PATZ1 (1)
- Particle correlations and fluctuations (1)
- Pb–Pb (1)
- Pediatric (1)
- Production Cross Section (1)
- Proton–proton (1)
- QCD (1)
- Quark gluon plasma (1)
- ROS (1)
- Rapidity Range (1)
- Relativistic heavy ion physics (1)
- Resolution Parameter (1)
- SLC7A11 (1)
- Single muons (1)
- Systematic Uncertainty (1)
- TR (1)
- Time Projection Chamber (1)
- Tracking (1)
- Transition radiation detector (1)
- Trigger (1)
- Xenon-based gas mixture (1)
- dE/dx (1)
- erastin (1)
- ferroptosis (1)
- heavy ion experiments (1)
- iron (1)
- lipocalin-2 (1)
- p-eIF2α (1)
- quark gluon plasma (1)
- spectra (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (425)
- Frankfurt Institute for Advanced Studies (FIAS) (393)
- Informatik (379)
- Medizin (4)
- Hochschulrechenzentrum (2)
- ELEMENTS (1)
- Gesellschaftswissenschaften (1)
Aim: In the CheckRad-CD8 trial patients with locally advanced head and neck squamous cell cancer are treated with a single cycle of induction chemo-immunotherapy (ICIT). Patients with pathological complete response (pCR) in the re-biopsy enter radioimmunotherapy. Our goal was to study the value of F-18-FDG PET/CT in the prediction of pCR after induction therapy.
Methods: Patients treated within the CheckRad-CD8 trial that additionally received FDG- PET/CT imaging at the following two time points were included: 3–14 days before (pre-ICIT) and 21–28 days after (post-ICIT) receiving ICIT. Tracer uptake in primary tumors (PT) and suspicious cervical lymph nodes (LN +) was measured using different quantitative parameters on EANM Research Ltd (EARL) accredited PET reconstructions. In addition, mean FDG uptake levels in lymphatic and hematopoietic organs were examined. Percent decrease (Δ) in FDG uptake was calculated for all parameters. Biopsy of the PT post-ICIT acquired after FDG-PET/CT served as reference. The cohort was divided in patients with pCR and residual tumor (ReTu).
Results: Thirty-one patients were included. In ROC analysis, ΔSUVmax PT performed best (AUC = 0.89) in predicting pCR (n = 17), with a decline of at least 60% (sensitivity, 0.77; specificity, 0.93). Residual SUVmax PT post-ICIT performed best in predicting ReTu (n = 14), at a cutpoint of 6.0 (AUC = 0.91; sensitivity, 0.86; specificity, 0.88). Combining two quantitative parameters (ΔSUVmax ≥ 50% and SUVmax PT post-ICIT ≤ 6.0) conferred a sensitivity of 0.81 and a specificity of 0.93 for determining pCR. Background activity in lymphatic organs or uptake in suspected cervical lymph node metastases lacked significant predictive value.
Conclusion: FDG-PET/CT can identify patients with pCR after ICIT via residual FDG uptake levels in primary tumors and the related changes compared to baseline. FDG-uptake in LN + had no predictive value.
Trial registry: ClinicalTrials.gov identifier: NCT03426657.